Advanced Enzyme Technologies LimitedPharmaceuticals & HealthcareADVENZYMES
Q1 FY27 concall · earnings callAdvanced Enzyme Technologies Limited
Advanced Enzyme Technologies reported a muted quarter impacted by sales reversals and global disruptions, but management maintains confidence in achieving double-digit annual growth.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue | ₹189.8 Cr | 2% YoY | |
| EBITDA | ₹51 Cr | -10% YoY | |
| EBITDA Margin | 27% | — | |
| PAT | ₹38.6 Cr | -5% YoY | |
| PAT Margin | 20% | — |
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹169.11 Cr+5.1% YoY+15.8% QoQ | ₹38.88 Cr-8.5% YoY+16.4% QoQ | ₹3.36-10.2% YoY+14.3% QoQ |
| Q2 FY25 | ₹146.09 Cr-7.4% YoY-5.5% QoQ | ₹33.39 Cr-5.1% YoY-4.5% QoQ | ₹2.94-4.5% YoY-3.6% QoQ |
| Q1 FY25 | ₹154.52 Cr+4.9% YoY-2.1% QoQ | ₹34.98 Cr+19.1% YoY+17.1% QoQ | ₹3.05+18.2% YoY+20.6% QoQ |
| Q4 FY24 | ₹157.81 Cr+13.8% YoY-1.9% QoQ | ₹29.87 Cr-7% YoY-29.7% QoQ | ₹2.53-11.8% YoY-32.4% QoQ |
| Q3 FY24 | ₹160.94 Cr+13.3% YoY+2% QoQ | ₹42.50 Cr+52.3% YoY+20.7% QoQ | ₹3.74+42.2% YoY+21.4% QoQ |
TL;DR
- Revenue of INR 1,898 million grew 2% YoY but declined 7% QoQ, impacted by an incremental INR 100 million sales reversal.
- EBITDA declined 10% YoY to INR 510 million with margin at 27%, due to lower top-line, elevated costs, and sales mix.
- Human Healthcare revenue declined 7% YoY, while Bioprocessing and Specialized Manufacturing grew 30% and 41% YoY respectively.
- The Board approved a buyback of INR 697 million and the acquisition of the remaining 4.28% stake in JC Biotech.
- Management expects double-digit growth for the year, with margins recovering to around 30%.
Said on the call
“Our top line for the quarter stood at INR 1,898 million, registering a 2% YoY growth. On a sequential basis, revenue declined by 7% compared to the previous quarter.”
From the Q&A
| Topic | What management said |
|---|---|
| U.S. Business Growth | Analysts pressed on persistently low growth in the U.S. market compared to industry rates; management cited geopolitical issues, a shift towards branding products for stickiness, and challenges in hiring, expecting 8-10% growth. |
| Capital Expenditure | Management clarified that the INR 123 crore CapEx includes INR 20 crore for normal spending, INR 50 crore for R&D, and the rest for growth, triggered by fermentation capacity utilization reaching 70-75%. |
| Sales Reversal Impact | Management explained the incremental INR 100 million sales reversal was due to goods in transit not reaching the customer for revenue recognition, and stated this amount has now been recorded. |
| Margin Outlook | Management expects EBITDA margins to recover to the normal level of about 30% for the year, aided by operational efficiency and cost optimization. |
| Product Concentration & New Launches | When asked about dependence on serratiopeptidase, management said they are working on new products in food, biocatalysis, animal feed, and detergent areas, but do not track product-wise sales. |
Guidance
- Management is confident in delivering sustainable revenue growth consistent with annual guidance.
- Expects double-digit growth for the year.
- Anticipates EBITDA margins to recover to the normal level of about 30%.
- Expects progressive momentum as the year advances.
Source
Summary written from the transcript filed by Advanced Enzyme Technologies Limited for the call held on 18 Aug 2026; published 18 Aug 2026, 18:47 IST.
More Q1 FY27 concalls ·How verification works ·Report an error